



To NASDAQ OMX Copenhagen A/S  
Announcement No. 08-10 / Copenhagen, March 25, 2010

**TopoTarget A/S**  
Symbion  
Fruebjergvej 3  
DK 2100 Copenhagen  
Denmark  
Tel: +45 39 17 83 92  
Fax: +45 39 17 94 92  
CVR-no: 25695771

[www.topotarget.com](http://www.topotarget.com)

## TopoTarget Announces Financial Results for the Year ended December 31, 2009

### **-Commencing 2010 with a strong cash position-**

**Copenhagen, Denmark - March 25, 2010 – TopoTarget A/S (NASDAQ OMX: TOPO) announced today financial results for the year ended December 31, 2009. In view of the activities carried out during the year, the financial performance is considered satisfactory.**

- **TopoTarget's cash and cash equivalents as at 31 December 2009 totalled DKK 130.2 million.** On 31 December 2008 cash and cash equivalents totalled DKK 108.0 million.
  - ✓ Taking into account the Spectrum deal sign-on fee of USD 30 million and Spectrum taking on 70% of the development costs, the sales proceeds from the Savene<sup>®</sup> sale and existing cash, TopoTarget has sufficient cash resources for at least two to three years, without taking into account revenue from future potential milestones.
  - ✓ TopoTarget completed a capital raise in July wherein the share capital of the Company was increased by 66,304,510 new shares raising gross proceeds of DKK 132.6 million.
- **The financial performance is considered satisfactory**
  - ✓ For the year 2009 the Group recorded a loss before tax and before write-downs of certain research and development projects of DKK 121.5 million compared to a loss before tax and before write-downs of DKK 212.6 million in 2008.
  - ✓ The sales income for Savene<sup>®</sup> and Totect<sup>®</sup> increased to DKK 39.7 million from DKK 39.1 million in 2008. The supply disruptions that we experienced in the US in 2009 have now been resolved.
  - ✓ A write-down of DKK 21.2 million (2008: DKK 93.5 million) has been made related to certain research and development projects acquired from third parties and recognised in the balance sheet at the time of acquisition. Such write-down does not affect the group cash flow for the year 2009.

#### **After the reporting period:**

- **New CEO**
  - ✓ Francois Martelet, MD has taken up the position of CEO of TopoTarget in order to add the necessary late-stage clinical development and marketing expertise to ensure a successful development and commercialisation of belinostat. Dr. Francois Martelet has a solid late-stage development and 18+ years of commercialisation experience from the international pharmaceutical industry.
- **Deals**
  - ✓ **US partner for belinostat**

TopoTarget entered into a Development and Commercialisation Agreement with Spectrum under which the parties agreed to co-develop and Spectrum to commercialise belinostat in North America and India with a right of first offer for China. Under the terms of the agreement TopoTarget received an upfront payment of USD 30 million (non conditional and non refundable) and the right to receive further payments of up to USD 320 million on the achievement of certain defined development and sales milestones. In addition TopoTarget will receive a double digit royalty on sales of belinostat as well as one million Spectrum shares. Spectrum commits to fund 100% of the costs of the ongoing pivotal PTCL study and TopoTarget will fund 100% of the ongoing phase 2 CUP study. Spectrum will pay 70% of future development costs of belinostat.
  - ✓ **Divesture of Savene<sup>®</sup> for Europe**

TopoTarget entered into an agreement with SpePharm Holding, BV who acquired the rights to Savene<sup>®</sup> for EUR 6 million (EUR 5 million plus the value of stock payable on settlement plus a double digit royalty on net sales capped at EUR 1 million). Totect<sup>®</sup>, the US trademark for the same product, will remain with TopoTarget and continue to be promoted by the TopoTarget US sales team.
- **New major investor**
  - ✓ TopoTarget announced that a notification was received from Försäkringsaktiebolaget Avanza Pension, that Avanza Pension's holdings of shares and voting rights have now exceeded 5% of TopoTarget's total share capital and total number of voting rights.

#### **Highlights of promising clinical results with belinostat in 2009**

- ✓ Significant achievements have been obtained during the ongoing clinical development.
- ✓ More than 700 patients have been treated and the product has shown an excellent activity, safety and tolerability profile.
- ✓ Belinostat has three important competitive advantages: The ability to be combined in full doses with a variety of anti-cancer therapeutic agents; Flexibility in administration as belinostat is available in oral as well as in parenteral administration forms and an excellent safety profile.
- ✓ The product, as an intravenous (IV) administration has shown clinical activity as monotherapy with results presented in a phase 2 study in PTCL patients at the 2009 annual conference in American Society of Haematology (ASH).
- ✓ The BelCap regimen is currently being tested in a randomised phase 2 global, multi-center trial in cancer of unknown primary (CUP) patients. This trial is being conducted in collaboration with key CUP opinion leaders both in the US and in Europe.

### Conference call

A teleconference will be held on 25 March 2010 at 2 pm local time. CEO Francois Martelet and CFO Tim Corcoran will present the 2009 Annual Report and answer questions. The teleconference will be conducted in English.

A presentation will be available on TopoTarget's website, [www.topotarget.com](http://www.topotarget.com), before the start of the conference call. To participate in the conference call please dial:

- From Denmark: 70 26 50 40
- Outside Denmark: +45 70 26 50 40

A replay of the conference call will be available approximately two hours after the conference call and until 1 April, 2010 at: +353 1 436 4267, pin code: 2564357#. From 26 March to 19 May 2010 a replay will be available on the TopoTarget homepage [www.topotarget.com](http://www.topotarget.com)

### TopoTarget A/S

For further information, please contact:

Ulla Hald Buhl	Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49

### Background information

#### About TopoTarget

TopoTarget (NASDAQ OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget currently focuses, in collaboration with Spectrum Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug candidate, Belinostat, which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within PTCL (peripheral T-cell lymphoma). TopoTarget's expertise in translational research is based on utilising its highly predictive in vivo and in vitro cancer models. TopoTarget is directing its efforts on key cancer targets, including HDACi, NAD<sup>+</sup>, mTOR, FASLigand and topoisomerase II inhibitors. The Company's first marketed product, Savene<sup>®</sup>/Totect<sup>®</sup>, was approved by EMEA in 2006 and the FDA in 2007, and is marketed by TopoTarget's own sales force in the US. For more information, please refer to [www.topotarget.com](http://www.topotarget.com).

#### TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.